Tag: Sofosbuvir

The number of BC PharmaCare covered hep C treatments has been increasing and so has the information gathered by the Hepatitis C Treatment Information Project. The Hep C TIP now has new pages dedicated to BC’s PharmaCare and the treatments that are covered by it. These pages are: Treatments Targeted Genotype Ribavirin with Pegylated Interferon… Read more »

CATIE HepCinfo Update 6.6

New warning issued for serious heart problems when Harvoni or sofosbuvir is taken with amiodarone The U.S. Food and Drug Administration (FDA) is warning that serious slowing of the heart rate (symptomatic bradycardia) can occur when the drug amiodarone, which is used to treat an irregular heartbeat, is taken together either with Harvoni or with… Read more »

CATIE’s HepCInfo Update 5.24

New and Noteworthy Harvoni cures 98% of Hep C and HIV co-infected participants with genotype 1 virus 98% of Hep C and HIV co-infected participants with genotype 1 virus who took Harvoni (ledipasvir + sofosbuvir) during a 12-week clinical trial were cured, reported researchers at the American Association for the Study of Liver Diseases (AASLD)… Read more »

CATIE: HepCinfo Update 5.23

New and Noteworthy Harvoni (ledipasvir + sofosbuvir) approved by Health Canada In October, Health Canada approved the hepatitis C medication Harvoni (ledipasvir + sofosbuvir) for people over the age of 18 with genotype 1 hepatitis C virus. In clinical trials, the cure rate for this combination was 94% to 100%. Ledipasvir and sofosbuvir are both… Read more »

CATIE’s HepCinfo Update 4.24

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:”Table Normal”; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:””; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:”Times New Roman”,”serif”;} New and Noteworthy New study estimates cases of hepatitis B and C, but experts warn figures may be too low A new federal government… Read more »

CATIE HepCinfo Update 4.22

New and Noteworthy FDA advisory committee recommends the approval of simeprevir and sofosbuvir The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously recommended the approval of two direct-acting antivirals for hepatitis C, simeprevir and sofosbuvir. The newer direct-acting antiviral medications are more effective, easier to take and have significantly fewer… Read more »

CTAC Patient Input Survey on Sofosbuvir

On October 15, 2013, CTAC conducted a webinar supporting our patient input submission for sofosbuvir, a new NS5B inhibitor to treat hepatitis C. This webinar was just one step you, people with lived experience and service providers can take to support this important patient input submission on sofosbuvir – a medication that stands to change… Read more »

Sofosbuvir Patient Input Webinar – Tuesday, October 15

SOFOSBUVIR PATIENT INPUT WEBINAR TUESDAY, OCTOBER 15, 2013, 2PM-3:30PM (EST) In preparation for our role in steering the Common Drug Review patient input submission for Sofosbuvir, a new HCV direct-acting antiviral, to treat HCV that is moving its way through the next steps of the regulatory approval process, we are hosting a national webinar to… Read more »

Pacific Hepatitis C Network: Understanding Sofosbuvir

This is an exciting time in the evolution of HCV treatment in Canada.  New approved treatment in the near future will offer patients the opportunity to achieve the highest SVR and cure.  The hope is that the new drug Sofosbuvir will meet many current unmet needs and provide patients with the confidence to seek treatment… Read more »